Keyphrases
Pancreatic Ductal Adenocarcinoma
100%
Pancreatic Cancer
70%
Gemcitabine
32%
Tumorigenesis
32%
Tumor
30%
Chemotherapy
28%
Oncogenic Ras
20%
Patient-derived Xenograft
20%
Pancreatic Duct Cells
19%
Metastatic Pancreatic Ductal Adenocarcinoma
19%
RalA
17%
Overall Survival
16%
Tumor Growth
16%
Nab-paclitaxel
15%
CCR2
15%
Transcriptome
15%
KRAS-mutant Cancer
15%
Extracellular Signal-regulated Kinase
15%
Chemoresistance
15%
Human Cells
15%
Colorectal Cancer
14%
Tumor Microenvironment
14%
NF-B
13%
Poor Prognosis
13%
Tumor Maintenance
12%
Resectable Pancreatic Cancer
12%
K-ras
12%
Gallbladder Cancer
11%
Oncogene
11%
RalB
11%
Targeted Treatment
11%
Inflammatory Pathways
11%
Tumor-associated Macrophages
11%
FOLFIRINOX
11%
Toll-like
11%
Cancer-associated Fibroblasts
10%
Gastrointestinal Cancer
10%
Cancer Patients
10%
Human Cancer
10%
Tumor Cells
10%
Pembrolizumab
10%
Phase Ib Study
10%
Neoadjuvant
10%
Comprehensive Characterization
10%
Metastatic Colorectal Cancer (mCRC)
10%
Liposomal Irinotecan
10%
Ulixertinib
10%
Diffuse Large B-cell Lymphoma (DLBCL)
10%
IRAK4
10%
Dose Escalation
10%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
76%
Pancreas Cancer
66%
Malignant Neoplasm
52%
Neoplasm
47%
Gemcitabine
31%
Disease
29%
Chemotherapy
28%
Clinical Trial
21%
Carcinogenesis
19%
Tumor Growth
16%
Progression Free Survival
16%
Drug Resistance
16%
Overall Survival
16%
Paclitaxel
16%
Fluorouracil
15%
Folinic Acid
14%
Bile Duct Carcinoma
12%
Digestive System Cancer
11%
Adenocarcinoma
11%
Oxaliplatin
10%
Irinotecan Sucrosofate
10%
Ulixertinib
10%
Colorectal Carcinoma
9%
Gallbladder Cancer
8%
Immunotherapy
8%
Tumor Microenvironment
7%
Adverse Event
7%
Phosphotransferase
6%
Receptor
6%
Diarrhea
6%
Irinotecan
6%
Biliary Tract Cancer
6%
Liver Cell Carcinoma
6%
Pancreas Carcinoma
6%
Focal Adhesion Kinase
6%
Janus Kinase 1
6%
Toxicity
6%
Cancer Model
5%
Toll Like Receptor 9
5%
Mitogen Activated Protein Kinase
5%
Fibrosis
5%
Focal Adhesion Kinase Inhibitor
5%
Metastasis
5%
Mouse Model
5%
Neutropenia
5%
Tosedostat
5%
Palbociclib
5%
Copper Nanoparticle
5%
Beta Chemokine
5%
Pembrolizumab
5%
Medicine and Dentistry
Pancreas Adenocarcinoma
77%
Pancreas Cancer
62%
Neoplasm
49%
Chemotherapy
35%
Disease
22%
Gemcitabine
21%
Malignant Neoplasm
21%
Drive
16%
Overall Survival
15%
Clinical Trial
14%
Stroma
13%
Immunotherapy
13%
Metastatic Carcinoma
13%
Cholangiocarcinoma
12%
Hepatocellular Carcinoma
11%
Radiation Therapy
11%
Ras Signaling
11%
Progression Free Survival
10%
Chemokine Receptor
10%
Gastrointestinal Cancer
10%
Diffuse Large B-Cell Lymphoma
10%
Gallbladder Cancer
9%
Surgery
9%
Cancer Associated Fibroblast
8%
Adenocarcinoma
8%
Cancer
7%
Tumor Cell
7%
Positron Emission Tomography
7%
Nuclear Factor
7%
Alternative Complement Pathway C3 C5 Convertase
7%
Colorectal Carcinoma
7%
B Cell
7%
Systemic Therapy
6%
Proteomics
6%
Phosphotransferase
6%
Diagnosis
6%
Drug Resistance
6%
Cancer Types
6%
Mitogen-Activated Protein Kinase
6%
Biliary Duct Cancer
6%
Polyethylene Terephthalate
6%
Tumor Progression
5%
Tumor Microenvironment
5%
Paclitaxel
5%
Fluorouracil
5%
Folinic Acid
5%
Oxaliplatin
5%
Cancer Therapy
5%
Fibrosis
5%
Immunity
5%